Skip to main content

Table 2 Patient Demographics and Test Characteristics

From: Performance of SARS-CoV-2 antigen testing in symptomatic and asymptomatic adults: a single-center evaluation

Symptomatic

Total

Cepheid + 

Cepheid −

Sofia + 

Sofia −

(A) Symptomatic

n

148

41

107

36

112

Average age, yrs (range)

44.1 (18–83)

46.3 (18–83)

43.3 (20–76)

47.2 (20–83)

43.2 (18–76)

Sex, male

42 (28.4%)

21 (51.2%)

21 (19.6%)

18 (50%)

24 (21.4%)

Symptoms

 Fever

29 (19%)

15 (36.6%)

14 (13.1%)

11 (30.6%)

18 (16.1%)

 Cough

76 (51.3%)

26 (63.4%)

50 (46.7%)

22 (61.1%)

54 (48.2%)

 Congestion

77 (52.0%)

26 (63.4%)

51 (47.6%)

24 (66.7%)

53 (47.3%)

 Shortness of breath

14 (9.5%)

4 (9.8%)

10 (9.3%)

4 (11.1%)

10 (8.9%)

 Headache

45 (30.4%)

11 (26.8%)

34 (31.8%)

10 (27.8%)

35 (31.3%)

 Sore throat

49 (33.1%)

9 (22.0%)

40 (37.4%)

8 (22.2%)

41 (36.6%)

 Loss of taste

17 (11.5%)

10 (24.4%)

7 (6.5%)

9 (25.0%)

8 (7.1%)

 Loss of smell

18 (12.2%)

10 (24.4%)

8 (7.5%)

9 (25.0%)

9 (8.0%)

 Abdominal pain

5 (3.4%)

1 (2.4%)

4 (3.7%)

1 (2.8%)

4 (3.6%)

 Nausea

12 (8.1%)

6 (14.6%)

6 (5.6%)

5 (13.9%)

7 (6.3%)

 Vomiting

8 (5.4%)

2 (4.9%)

6 (5.6%)

2 (5.6%)

6 (5.4%)

 Diarrhea

14 (9.5%)

3 (7.3%)

11 (10.3%)

3 (8.3%)

11 (9.8%)

 Myalgia

32 (21.6%)

9 (22.0%)

23 (21.5%)

9 (25.0%)

23 (20.5%)

 Fatigue

31 (20.9%)

6 (14.6%)

25 (23.3%)

4 (11.1%)

27 (24.1%)

 Other (Chills)

24 (16.2%)

9 (22.0%)

15 (14.0%)

9 (25.0%)

15 (13.4%)

Total number of symptoms, average (range)

3.0 (1–7)

3.6 (1–7)

2.8 (1–7)

3.6 (1–7)

2.9 (1–7)

No. days of symptoms prior to test, average (range)

3.6 (1–7)

3.8 (1–7)

3.5 (1–7)

3.7 (2–7)

3.6 (1–7)

Known exposure

31 (20.9%)

12 (29.3%)

19 (17.7%)

11 (30.6%)

20 (17.9%)

No. days post-exposure until test, average (range)

5.3 (1–12)

4.8 ( 1–7)

5.8 (1–12)

5.1 (1–7)

5.5 (1–12)

Asymptomatic

Total

Cepheid + 

Cepheid −

Sofia + 

Sofia −

(B) Asymptomatic.

n

144

6

138

2

142

Average age, years (range)

38.6 (17–80)

46.7 (28–68)

38.2 (17–80)

50.5 (34–67)

38.8(17–80)

Sex, male*

51 (41.1%)

2 (33.3%)

49 (41.5%)

1 (50.0%)

50 (41.0%)

Reason for testing

Exposure

8 (5.6%)

2 (33.3%)

6 (4.3%)

0 (0%)

8 (5.6%)

Required for work

3 (2.1%)

1 (16.7%)

2 (1.4%)

0 (0%)

3 (2.1%)

Required for travel/Re-entry

10 (6.9%)

0 (0%)

10 (7.2%)

0 (0%)

10 (7.0%)

Required for procedure

33 (22.9%)

1 (16.7%)

32 (23.2%)

1 (50%)

32 (22.5%)

Asymptomatic Surveillance

47 (32.6%)

0 (0%)

47 (34.1%)

0 (0%)

47 (33.1%)

Unknown

43 (29.9%)

2 (33.3%)

41 (29.7%)

1 (50%)

42 (29.6%)

Known exposure

7 (4.9%)

2 (33.3%)

5 (3.6%)

0 (0%)

7 (5.0%)

No. days post-exposure to test, average (range)

3.4 (1–7)

2.5 (1–4)

4.0 (1–7)

N/A

3.4 (1–7)

  1. *Total analyzed is 122 due to no sex identification denoted in the chart